Startups
GSK
London, United Kingdom
London-headquartered public biopharmaceutical company formed through the Glaxo Wellcome and SmithKline Beecham merger in 2000, with predecessor businesses dating to 1715. GSK develops specialty medicines and vaccines across respiratory, immunology and inflammation, oncology and infectious diseases, including HIV through ViiV Healthcare. It combines human genetics, functional genomics, artificial intelligence and machine learning in drug discovery. Its technology and neuroscience relevance includes strategic research alliances in neurodegeneration and corporate equity investments in discovery platforms such as Relation Therapeutics and human-genetics company 23andMe. Luke Miels became CEO on 1 January 2026; the current board and Executive Committee contain 26 distinct named people. Commercial research payments, licence milestones, acquisitions, share buybacks and ordinary market trading are distinct from equity financing. This profile represents the parent corporation rather than GSK Ventures, Action Potential Venture Capital or independently managed SR One.
Founded 2000
Team
 Anne BealIndependent Non-Executive Director |
 Charles BancroftSenior Independent Non-Executive Director |
 David RedfernPresident Corporate Development |
 Deborah WaterhouseCEO, ViiV Healthcare and President, Global Health, GSK |
 Elizabeth McKee AndersonIndependent Non-Executive Director |
 Gavin ScreatonIndependent Non-Executive Director |
 Hal BarronNon-Executive Director |
 Harry DietzIndependent Non-Executive Director |
 James FordSVP and Group General Counsel, Legal and Compliance |
 Jeannie LeeIndependent Non-Executive Director |
 Jonathan SymondsChair |
 Julie BrownChief Financial Officer · Executive Director |
 Luke MielsChief Executive Officer · Executive Director |
 Lynn BaxterPresident, Europe |
 Maya Martinez-DavisPresident, US |
 Mike CrichtonPresident, International |
 Mondher MahjoubiChief Patient Officer |
 Nina MojasPresident, Global Product Strategy |
 Phil ThomsonPresident, Global Affairs |
 Regis SimardPresident, Global Supply Chain |
 Roanne ParryChief People Officer |
 Roy JakobsIndependent Non-Executive Director |
 Shobie RamakrishnanChief Digital and Technology Officer |
 Tony WoodChief Scientific Officer |
 Vishal SikkaIndependent Non-Executive Director |
 Wendy BeckerIndependent Non-Executive Director |
Investments
| $15M2024-12-10 |  Relation Therapeutics | GSK |
| $50M2023-01-26 |  Wave Life Sciences | GSK |
| $175M2022-03-23 |  LifeMine Therapeutics | GSK |
| $300M2018-07-25 |  23andMe | GSK |